TY - JOUR AU - McCluggage, W. G. PY - 2011 DA - 2011// TI - Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis JO - Pathol VL - 43 UR - https://doi.org/10.1097/PAT.0b013e328348a6e7 DO - 10.1097/PAT.0b013e328348a6e7 ID - McCluggage2011 ER - TY - JOUR PY - 2011 DA - 2011// TI - Integrated genomic analyses of ovarian carcinoma JO - Nature VL - 474 UR - https://doi.org/10.1038/nature10166 DO - 10.1038/nature10166 ID - ref2 ER - TY - JOUR AU - Dasari, S. AU - Bernard Tchounwou, P. PY - 2014 DA - 2014// TI - Cisplatin in cancer therapy: molecular mechanisms of action JO - Eur J Pharmacol VL - 740C UR - https://doi.org/10.1016/j.ejphar.2014.07.025 DO - 10.1016/j.ejphar.2014.07.025 ID - Dasari2014 ER - TY - JOUR AU - Slichenmyer, W. J. AU - Rowinsky, E. K. AU - Donehower, R. C. AU - Kaufmann, S. H. PY - 1993 DA - 1993// TI - The current status of camptothecin analogues as antitumor agents JO - J Natl Cancer Inst VL - 85 UR - https://doi.org/10.1093/jnci/85.4.271 DO - 10.1093/jnci/85.4.271 ID - Slichenmyer1993 ER - TY - JOUR AU - Lorusso, D. AU - Pietragalla, A. AU - Mainenti, S. AU - Masciullo, V. AU - Vagno, G. AU - Scambia, G. PY - 2010 DA - 2010// TI - Review role of topotecan in gynaecological cancers: current indications and perspectives JO - Crit Rev Oncol Hematol VL - 74 UR - https://doi.org/10.1016/j.critrevonc.2009.08.001 DO - 10.1016/j.critrevonc.2009.08.001 ID - Lorusso2010 ER - TY - JOUR AU - Kim, M. K. AU - Min, D. J. AU - Wright, G. AU - Goldlust, I. AU - Annunziata, C. M. PY - 2014 DA - 2014// TI - Loss of compensatory pro-survival and anti-apoptotic modulator, IKKepsilon, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21 JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.2665 DO - 10.18632/oncotarget.2665 ID - Kim2014 ER - TY - JOUR AU - Goto, H. AU - Izawa, I. AU - Li, P. AU - Inagaki, M. PY - 2012 DA - 2012// TI - Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy? JO - Cancer Sci VL - 103 UR - https://doi.org/10.1111/j.1349-7006.2012.02280.x DO - 10.1111/j.1349-7006.2012.02280.x ID - Goto2012 ER - TY - JOUR AU - Rawlinson, R. AU - Massey, A. J. PY - 2014 DA - 2014// TI - GammaH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-483 DO - 10.1186/1471-2407-14-483 ID - Rawlinson2014 ER - TY - JOUR AU - Parsels, L. A. AU - Qian, Y. AU - Tanska, D. M. AU - Gross, M. AU - Zhao, L. AU - Hassan, M. C. PY - 2011 DA - 2011// TI - Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-3082 DO - 10.1158/1078-0432.CCR-10-3082 ID - Parsels2011 ER - TY - JOUR AU - Dent, P. AU - Tang, Y. AU - Yacoub, A. AU - Dai, Y. AU - Fisher, P. B. AU - Grant, S. PY - 2011 DA - 2011// TI - CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle JO - Mol Interv VL - 11 UR - https://doi.org/10.1124/mi.11.2.11 DO - 10.1124/mi.11.2.11 ID - Dent2011 ER - TY - JOUR AU - Tao, Z. F. AU - Lin, N. H. PY - 2006 DA - 2006// TI - Chk1 inhibitors for novel cancer treatment JO - Anticancer Agents Med Chem VL - 6 UR - https://doi.org/10.2174/187152006777698132 DO - 10.2174/187152006777698132 ID - Tao2006 ER - TY - JOUR AU - Domcke, S. AU - Sinha, R. AU - Levine, D. A. AU - Sander, C. AU - Schultz, N. PY - 2013 DA - 2013// TI - Evaluating cell lines as tumour models by comparison of genomic profiles JO - Nat Commun VL - 4 UR - https://doi.org/10.1038/ncomms3126 DO - 10.1038/ncomms3126 ID - Domcke2013 ER - TY - JOUR AU - Langdon, S. P. AU - Lawrie, S. S. AU - Hay, F. G. AU - Hawkes, M. M. AU - McDonald, A. AU - Hayward, I. P. PY - 1988 DA - 1988// TI - Characterization and properties of nine human ovarian adenocarcinoma cell lines JO - Cancer Res VL - 48 ID - Langdon1988 ER - TY - JOUR AU - Barretina, J. AU - Caponigro, G. AU - Stransky, N. AU - Venkatesan, K. AU - Margolin, A. A. AU - Kim, S. PY - 2012 DA - 2012// TI - The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity JO - Nature VL - 483 UR - https://doi.org/10.1038/nature11003 DO - 10.1038/nature11003 ID - Barretina2012 ER - TY - JOUR AU - Blasina, A. AU - Hallin, J. AU - Chen, E. AU - Arango, M. E. AU - Kraynov, E. AU - Register, J. PY - 2008 DA - 2008// TI - Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 JO - Mol Cancer Ther VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-07-2391 DO - 10.1158/1535-7163.MCT-07-2391 ID - Blasina2008 ER - TY - JOUR AU - Aris, S. M. AU - Pommier, Y. PY - 2012 DA - 2012// TI - Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762 JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-2579 DO - 10.1158/0008-5472.CAN-11-2579 ID - Aris2012 ER - TY - JOUR AU - Huntoon, C. J. AU - Flatten, K. S. AU - Wahner Hendrickson, A. E. AU - Huehls, A. M. AU - Sutor, S. L. AU - Kaufmann, S. H. PY - 2013 DA - 2013// TI - ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-13-0110 DO - 10.1158/0008-5472.CAN-13-0110 ID - Huntoon2013 ER - TY - JOUR AU - Xiao, Y. AU - Ramiscal, J. AU - Kowanetz, K. AU - Nagro, C. AU - Malek, S. AU - Evangelista, M. PY - 2013 DA - 2013// TI - Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-13-0404 DO - 10.1158/1535-7163.MCT-13-0404 ID - Xiao2013 ER - TY - JOUR AU - Walton, M. I. AU - Eve, P. D. AU - Hayes, A. AU - Valenti, M. R. AU - Haven Brandon, A. K. AU - Box, G. PY - 2012 DA - 2012// TI - CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-1322 DO - 10.1158/1078-0432.CCR-12-1322 ID - Walton2012 ER - TY - JOUR AU - Daud, A. I. AU - Ashworth, M. T. AU - Strosberg, J. AU - Goldman, J. W. AU - Mendelson, D. AU - Springett, G. PY - 2015 DA - 2015// TI - Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as Monotherapy and in combination with gemcitabine in patients with advanced solid tumors JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.57.5027 DO - 10.1200/JCO.2014.57.5027 ID - Daud2015 ER - TY - JOUR AU - Pujade-Lauraine, E. AU - Hilpert, F. AU - Weber, B. AU - Reuss, A. AU - Poveda, A. AU - Kristensen, G. PY - 2014 DA - 2014// TI - Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.51.4489 DO - 10.1200/JCO.2013.51.4489 ID - Pujade-Lauraine2014 ER - TY - JOUR AU - Vergote, I. AU - Schilder, R. J. AU - Pippitt, C. H. AU - Wong, S. AU - Gordon, A. N. AU - Scudder, S. PY - 2014 DA - 2014// TI - A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer JO - Gynecol Oncol VL - 135 UR - https://doi.org/10.1016/j.ygyno.2014.07.003 DO - 10.1016/j.ygyno.2014.07.003 ID - Vergote2014 ER - TY - JOUR AU - Lee, J. M. AU - Hays, J. L. AU - Annunziata, C. M. AU - Noonan, A. M. AU - Minasian, L. AU - Zujewski, J. A. PY - 2014 DA - 2014// TI - Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses JO - J Natl Cancer Inst VL - 106 UR - https://doi.org/10.1093/jnci/dju089 DO - 10.1093/jnci/dju089 ID - Lee2014 ER - TY - JOUR AU - Bryant, C. AU - Rawlinson, R. AU - Massey, A. J. PY - 2014 DA - 2014// TI - Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-570 DO - 10.1186/1471-2407-14-570 ID - Bryant2014 ER -